Show simple item record

dc.contributor.authorKristjánsson, Valdimar B
dc.contributor.authorLund, Sigrún H
dc.contributor.authorGröndal, Gerður
dc.contributor.authorSveinsdóttir, Signý V
dc.contributor.authorAgnarsson, Hjálmar R
dc.contributor.authorJónasson, Jón G
dc.contributor.authorBjörnsson, Einar S
dc.date.accessioned2021-01-11T15:30:07Z
dc.date.available2021-01-11T15:30:07Z
dc.date.issued2020-12-05
dc.date.submitted2021-01
dc.identifier.citationKristjánsson VB, Lund SH, Gröndal G, Sveinsdóttir SV, Agnarsson HR, Jónasson JG, Björnsson ES. Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scand J Gastroenterol. 2021 Jan;56(1):46-52. doi: 10.1080/00365521.2020.1854847.en_US
dc.identifier.pmid33280485
dc.identifier.doi10.1080/00365521.2020.1854847
dc.identifier.urihttp://hdl.handle.net/2336/621624
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractObjective: Immune-mediated diseases are on the rise after the introduction of powerful immunomodulating drugs. The objective of this study was to determine the population-based incidence rate of inflammatory bowel disease (IBD) among patients treated with the monoclonal antibody rituximab in Iceland and compare it to the baseline incidence rate of IBD in the general population. Methods: We identified all patients treated with rituximab in Iceland from 2001 to 2018 through a central medicine database. IBD cases were indexed from medical records and ICD-10 codes and further confirmed by colonoscopy- and pathology reports. An experienced pathologist compared the pathology of IBD cases with matched controls of IBD patients. Results: Lymphomas and related neoplasms were the most frequent indication for treatment with rituximab (n = 367) among the 651 patients included in the analysis. Following treatment, seven patients developed IBD: two cases of Crohn's disease, three with ulcerative colitis, and two with indeterminate IBD. The incidence rate of IBD among rituximab treated patients was 202 cases per 100,000 person-years. Comparing our data to IBD incidence in Iceland, rituximab treated patients have an age-adjusted hazard ratio of 6.6 for developing IBD. The risk did not correlate with dose or treatment duration. Prior diagnosis of an autoimmune illness did not increase the risk of IBD in rituximab treated patients. Conclusions: Patients on rituximab have a sixfold increased risk of developing IBD compared to the general population. This risk was not affected by the indication for treatment and was not associated with concurrent immune-mediated diseases. Summary This population-based retrospective cohort study included all patients receiving treatment with rituximab between 2001 and 2018 in Iceland and identified a sixfold increased risk of developing IBD when compared to the general population. Keywords: IBD-basic; IBD-clinical; Immunology; colonic-disorders; endoscopy-general.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.urlhttps://www.tandfonline.com/doi/full/10.1080/00365521.2020.1854847?needAccess=trueen_US
dc.subjectIBD-basicen_US
dc.subjectIBD-clinicalen_US
dc.subjectImmunologyen_US
dc.subjectcolonic-disordersen_US
dc.subjectendoscopy-generalen_US
dc.subjectRituximaben_US
dc.subject.meshInflammatory Bowel Diseasesen_US
dc.titleIncreased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018.en_US
dc.typeArticleen_US
dc.identifier.eissn1502-7708
dc.contributor.department1Faculty of Medicine, University of Iceland, Reykjavík, Iceland. 2Department of Internal Medicine, National University Hospital, Reykjavík, Iceland. 3Department of Pathology, National University Hospital, Reykjavík, Iceland. 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, National University Hospital, Reykjavík, Iceland.en_US
dc.identifier.journalScandinavian journal of gastroenterologyen_US
dc.rights.accessClosed - Lokaðen_US
dc.departmentcodeRHE12
dc.departmentcodePTT12
dc.departmentcodeHEM12
dc.departmentcodeGAS12
dc.source.journaltitleScandinavian journal of gastroenterology
dc.source.volume56
dc.source.issue1
dc.source.beginpage46
dc.source.endpage52
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record